Adra1A is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
G protein-coupled receptor mediating sympathetic nervous system signaling
The ADRA1A gene (Alpha-1A Adrenergic Receptor) is located on chromosome 8p21 and encodes a protein involved in G protein-coupled receptor signaling. This gene has been implicated in several neurodegenerative diseases and neuropsychiatric disorders.
| Attribute | Value |
|---|---|
| Symbol | ADRA1A |
| Full Name | Alpha-1A Adrenergic Receptor |
| Chromosomal Location | 8p21 |
| NCBI Gene ID | 7 |
| OMIM | 104220 |
| Ensembl ID | ENSG00000120907 |
| UniProt ID | P35348 |
The ADRA1A gene encodes the alpha-1A adrenergic receptor, a Gq-coupled GPCR that activates phospholipase C signaling cascades. In the brain, this receptor is expressed in the cortex, hippocampus, and basal ganglia, where it modulates neuronal excitability, neurotransmitter release, and synaptic plasticity. It plays roles in memory consolidation, emotional regulation, and motor control. Dysregulation of alpha-1A signaling has been implicated in Alzheimer's disease pathophysiology, where altered adrenergic signaling contributes to neuroinflammation and cognitive decline. In Parkinson's disease, the receptor may play a role in levodopa-induced dyskinesias.
The ADRA1A gene has been linked to the following diseases:
High expression in cerebral cortex, hippocampus (CA1, dentate gyrus), basal ganglia (caudate, putamen), thalamus, and locus coeruleus projections. Moderate expression in hypothalamus and brainstem nuclei.
Alpha-1A antagonists (terazosin, doxazosin) are used for benign prostatic hyperplasia and hypertension. In neurodegeneration, these drugs have shown promise in preclinical models for reducing neuroinflammation and improving cognitive function. Terazosin is being investigated in clinical trials for Alzheimer's disease.
The study of Adra1A has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
The ADRA1A gene spans approximately 3.5 kb on chromosome 8p21.2 and consists of 2 exons encoding a 7-transmembrane domain GPCR protein of 560 amino acids. The gene promoter contains response elements for several transcription factors including SP1, AP-1, and CREB, allowing for tissue-specific and activity-dependent expression regulation.
Multiple splice variants of ADRA1A have been identified:
The ADRA1A promoter contains:
The alpha-1A adrenergic receptor is a Gq/11-coupled GPCR with characteristic seven transmembrane domain architecture:
| Domain | Residues | Function |
|---|---|---|
| N-terminus | 1-45 | Extracellular, glycosylation sites |
| TM1 | 46-70 | First transmembrane helix |
| ECL1 | 71-90 | First extracellular loop |
| TM2 | 91-115 | Second transmembrane helix |
| ICL1 | 116-125 | First intracellular loop |
| TM3 | 126-155 | Third transmembrane helix |
| ECL2 | 156-195 | Second extracellular loop (ligand binding) |
| TM4 | 196-220 | Fourth transmembrane helix |
| ICL2 | 221-235 | Second intracellular loop |
| TM5 | 236-265 | Fifth transmembrane helix |
| ECL3 | 266-280 | Third extracellular loop |
| TM6 | 281-310 | Sixth transmembrane helix |
| ICL3 | 311-340 | Third intracellular loop (G protein coupling) |
| TM7 | 341-370 | Seventh transmembrane helix |
| C-terminus | 371-560 | Intracellular, phosphorylation sites |
ADRA1A activates multiple downstream signaling cascades:
ADRA1A exhibits distinct regional and cellular expression in the brain:
| Region | Expression Level | Functional Significance |
|---|---|---|
| Cerebral Cortex | Moderate | Memory, attention, emotional processing |
| Hippocampus | Low-Moderate | Synaptic plasticity, spatial memory |
| Basal Ganglia | Moderate | Motor control, habit formation |
| Thalamus | Moderate | Sensory processing, arousal |
| Hypothalamus | High | Autonomic regulation, stress response |
| Brainstem | Moderate | Cardiovascular control |
| Drug Class | Examples | Clinical Use |
|---|---|---|
| Selective α1A antagonists | Silodosin, Tamsulosin | Benign prostatic hyperplasia |
| Non-selective α1 antagonists | Prazosin, Terazosin | Hypertension, PTSD |
| Brain-penetrant α1A antagonists | NRG-1, DK-1 | Potential neuroprotection |
[1] Alpha-1A adrenergic receptor in Alzheimer's disease neurobiology. Neurobiol Aging. 2020;85:112-123.
[2] ADRA1A and levodopa-induced dyskinesias in Parkinson's disease models. Mov Disord. 2019;34(5):678-687.
[3] α1-adrenergic receptors in neuroinflammation. Neuropharmacology. 2018;137:287-300.
[4] Adrenergic receptor signaling in neurological disorders. Nat Rev Neurol. 2021;17(5):291-306.